Amrinone

Amrinone

File:Amrinone.svg
Systematic (IUPAC) name
5-amino-3,4'-bipyridin-6(1H)-one
Clinical data
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Intravenous
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Bioavailability	n/a
Protein binding	10 to 49%
Metabolism	Hepatic
Biological half-life	5 to 8 hours
Excretion	Renal (63%) and fecal (18%)
Identifiers
CAS Number	60719-84-8
ATC code	C01CE01 (WHO)
PubChem	CID 3698
ChemSpider	3570
Chemical data
Formula	C10H9N3O
Molar mass	187.198 g/mol[[]]
(verify)

Amrinone (INN) or inamrinone (USAN, changed in 2000 to prevent confusion with amiodarone), trade name Inocor, is a pyridine phosphodiesterase 3 inhibitor.

Uses

It is used in the treatment of congestive heart failure.

It has been studied for use before coronary artery bypass surgery.

Actions

Increases cardiac contractility, vasodilator. Acts by inhibiting the breakdown of both cAMP and cGMP by the phosphodiesterase (PDE3) enzyme.

Indications

Short-term management of severe CHF (not used long term because of increased mortality, probably due to heart failure).

Contraindications

Patients with history of hypersensitivity to the drug.

Precautions

May increase myocardial ischemia. Blood pressure, pulse, and EKG should be constantly monitored. Amrinone should only be diluted with normal saline or 1/2 normal saline; no dextrose solutions should be used. Furosemide should not be administered into an IV line delivering Amrinone.

Side effects

Thrombocytopenia, hepatotoxicity, arrhythmia, nausea, and vomiting.

Routes

IV bolus and infusion as described earlier.

Pediatric dosage

Safety in children has not been established.

References

de:Amrinon uk:Амрінон